Nektar seeks CEO
Executive Summary
Nektar Therapeutics has formed a CEO search committee to appoint a successor to replace chief exec Ajit Gill, who will retire March 17. Gill announced his resignation following the approval of the inhaled insulin treatment Exubera, for which Nektar developed the inhaler. Approval marks an "appropriate time to bring in a new CEO to lead Nektar in its next phase of growth to a more products-focused drug delivery company," firm says. Executive Chairman and former CEO Robert Chess will serve as acting CEO following Gill's departure...
Nektar Therapeutics has formed a CEO search committee to appoint a successor to replace chief exec Ajit Gill, who will retire March 17. Gill announced his resignation following the approval of the inhaled insulin treatment Exubera , for which Nektar developed the inhaler. Approval marks an "appropriate time to bring in a new CEO to lead Nektar in its next phase of growth to a more products-focused drug delivery company," firm says. Executive Chairman and former CEO Robert Chess will serve as acting CEO following Gill's departure.... |